{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-25-000032","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.171389+00:00","generated_at":"2026-05-21T01:45:28.926720+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"vTv Therapeutics appoints Michael Tung as CFO; reinitiates Phase 3 T1D trial","bullets":["Michael Tung appointed EVP and CFO effective May 19, 2025; base salary $450,000, target bonus 40%.","Tung brings 20+ years finance experience; previously CFO at AdvanCell, VP at FibroGen.","Company reinitiated screening in CATT1 Phase 3 trial for cadisegliatin, oral T1D adjunct to insulin.","Employment agreement includes 45,000 stock option grant, 9-month severance, 9-month non-compete.","No prior CFO departure disclosed; appointment comes at 'critical inflection point' per CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-25-000032","json":"https://secwatch.observer/filing/0001641489-25-000032.json","markdown":"https://secwatch.observer/filing/0001641489-25-000032.md","text":"https://secwatch.observer/filing/0001641489-25-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000032/0001641489-25-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000032/vtvt-20250519.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T01:45:28.926720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af2e3b05ac","claim":"Michael Tung was appointed as executive vice president and chief financial officer at vTv Therapeutics Inc..","evidence_excerpt":"On May 19, 2025, vTv Therapeutics Inc. (the “Company”) announced that the Company has appointed Michael Tung as executive vice president and chief financial officer of the Company, effective as of May 19, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000032/0001641489-25-000032-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"executive vice president and chief financial officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}